Chiltern has entered an agreement to acquire Theorem Clinical Research. The combined company will operate under the name Chiltern and will have global reach — most notably in China and Japan — as well as new service offerings for medical devices and diagnostics, clinical analytics and clinical supplies. Financial terms were not disclosed. The transaction, subject to customary regulatory and closing conditions, is expected to close in the next few weeks.
 
Chiltern, a UK-based CRO, has three specialized business units: Chiltern Biopharma, with expertise in respiratory, anti-infectives/vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, which manages all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a FSP offering resourcing and staffing solutions. Chiltern has 2,200 employees across 45 countries.
 
Theorem, headquartered in King of Prussia, PA, is a global provider of comprehensive clinical services with staff throughout the Americas, Europe and Asia-Pacific. Theorem is focused on analytic-based development, combination trials and personal data applications to simplify complex trials.
 
“This is a direct response to client demand for a clinical research partner that can provide scientific and operating strengths globally, in a responsive and flexible way,” said Dr. Jim Esinhart, Chiltern chief executive officer. “This transaction will bring together more than 3,700 people in more than 45 countries dedicated to the philosophy of “Designed Around You.”
 
“Chiltern and Theorem have carved out complementary niches, even across key geographies,” said Dr. John Potthoff, Theorem president and chief executive officer. “In key areas, our capabilities will dovetail into current Chiltern operations — this is a mutually beneficial deal.”